-
公开(公告)号：US20180221419A1
公开(公告)日：2018-08-09
申请号：US15947304
申请日：2018-04-06
申请人： JangoBio, LLC
CPC分类号： A61K35/545 , A61K9/0019 , A61K31/566 , A61K31/568 , A61K31/57 , A61K35/15 , A61K35/52 , A61K35/54 , A61K35/55 , A61P5/06 , A61P5/24 , C07K14/59
摘要： Methods are described for differentiating stem and post-natal cells into sex hormone-producing cells that can be administered to a patient autologously or allogeneically in order to maintain in balance, or rebalance, their hypothalamic-pituitary-gonadal (HPG) axis.
-
公开(公告)号：US20180201929A1
公开(公告)日：2018-07-19
申请号：US15743349
申请日：2016-07-08
发明人： James Butler , Kevin Fitzgerald , Gregory Hinkle , Brian Bettencourt , Huilei Xu
IPC分类号： C12N15/113 , A61P5/06
CPC分类号： C12N15/113 , A61P5/06 , C12N15/1136 , C12N2310/14 , C12N2310/315 , C12N2310/321 , C12N2310/322 , C12N2310/3341 , C12N2310/3515 , C12N2310/3521 , C12N2310/3533
摘要： The present invention relates to RNAi agents, e.g., double stranded RNAi agents, targeting the insulin-like growth factor binding protein, acid labile subunit (IGFALS) gene or the insulin-like growth factor 1 (IGF-1) gene, methods of using such double stranded RNAi agents to inhibit expression of an IGFALS gene or an IGF-1 gene, and methods of treating subjects having an IGF system-associated disorder.
-
公开(公告)号：US20240245749A1
公开(公告)日：2024-07-25
申请号：US18599127
申请日：2024-03-07
申请人： Amryt Endo, Inc.
发明人： Roni MAMLUK , Sam L. TEICHMAN
CPC分类号： A61K38/08 , A61K9/0053 , A61K9/4858 , A61K38/31 , A61P5/06
摘要： Methods of treating acromegaly in a subject are described herein. Exemplary methods include orally administering to the subject at least once daily at least one dosage form comprising octreotide, wherein the octreotide in each dosage form is 20 mg, and wherein the administering occurs at least 1 hour before a meal or at least 2 hours after a meal.
-
公开(公告)号：US20240166710A1
公开(公告)日：2024-05-23
申请号：US18282844
申请日：2022-03-17
申请人： Pfizer Inc. , OPKO Biologics Ltd.
CPC分类号： C07K14/61 , A61P5/06 , G01N33/74 , G01N2333/65 , G01N2800/52
摘要： The subject matter described herein is directed to methods of treating growth hormone related disorders by administering a long-acting recombinant human growth hormone. In another embodiment, a long-acting recombinant human growth hormone is administered in a composition or the combination is administered separately to treat growth deficiency in a subject previously treated with a once daily rhGH therapy.
-
公开(公告)号：US20240082343A1
公开(公告)日：2024-03-14
申请号：US18514644
申请日：2023-11-20
申请人： Amryt Endo, Inc.
发明人： Roni MAMLUK , Sam L. TEICHMAN
CPC分类号： A61K38/08 , A61K9/0053 , A61K9/4858 , A61K38/31 , A61P5/06
摘要： Methods of treating acromegaly in a subject are described herein. Exemplary methods include orally administering to the subject at least once daily at least one dosage form comprising octreotide, wherein the octreotide in each dosage form is 20 mg, and wherein the administering occurs at least 1 hour before a meal or at least 2 hours after a meal.
-
公开(公告)号：US20180244754A1
公开(公告)日：2018-08-30
申请号：US15758199
申请日：2016-09-08
IPC分类号： C07K14/765 , C07K14/61 , A61P3/00 , A61P43/00 , A61P5/06
CPC分类号： C07K14/765 , A61K38/00 , A61P3/00 , A61P5/06 , A61P43/00 , C07K14/61 , C07K19/00 , C07K2319/00 , C07K2319/31 , C12N5/16 , C12N15/09
摘要： Disclosed are a human serum albumin mutant that can be linked to a physiologically active protein to increase the stability of the protein in the blood, as well as a resulting protein produced by linking with the mutant. The protein produced by linking with the mutant consists of a human serum albumin mutant comprising the amino acid sequence set forth as SEQ ID NO:3 or an amino acid sequence that, in comparison with it, lacks not more than 10 amino acid residues and/or has not more than 10 amino acid residues replaced, with the proviso that the asparagine residue occurring at position 318 and the threonine at position 320 from the N-terminus of the amino acid sequence set forth as SEQ ID NO:3 are preserved and linked by peptide bonds via a single amino acid residue (X) except proline placed between those two amino acid residues, and a physiologically active protein linked to the mutant.
-
公开(公告)号：US20240245663A1
公开(公告)日：2024-07-25
申请号：US18623761
申请日：2024-04-01
申请人： Lumos Pharma, Inc.
发明人： Alpa B. Parikh , John C. McKew
CPC分类号： A61K31/438 , A61K9/2077 , A61K9/2846 , A61K47/24 , A61K47/26 , A61K47/36 , A61K47/38 , A61P5/06
摘要： The present disclosure relates to pharmaceutical solid forms and pharmaceutical compositions comprising ibutamoren or a pharmaceutically acceptable salt thereof, and methods for administering to a pediatric subject for treating growth hormone deficiency.
-
公开(公告)号：US11884646B2
公开(公告)日：2024-01-30
申请号：US17688016
申请日：2022-03-07
IPC分类号： C07D401/12 , A61P5/06
CPC分类号： C07D401/12 , A61P5/06 , C07B2200/13
摘要： Provided are various embodiments relating to fumarate salt of (R)-3-(1-(2,3-dichloro-4-(pyrazin-2-yl)phenyl)-2,2,2-trifluoroethyl)-1-methyl-1-(1-methylpiperidin-4-yl) urea, and methods of producing and using the same to treat conditions and disorders associated with an increase of ghrelin level, such as food abuse, alcohol addiction, and other disorders (e.g., Prader-Willi syndrome). Also provided are various embodiments relating to crystalline HM04 free base, different crystalline forms of HM04 fumarate salt, and methods of producing the same.
-
公开(公告)号：US11744837B2
公开(公告)日：2023-09-05
申请号：US16945599
申请日：2020-07-31
发明人： Andreas Moraitis
CPC分类号： A61K31/567 , A61P3/10 , A61P5/06 , A61P5/10 , G01N33/743 , A61K45/06
摘要： This invention provides new methods for a) identifying Cushing's Syndrome patients at high risk of developing hypokalemia during glucocorticoid receptor modulator (GRM) treatment, and b) for prophylactically treating such patients to prevent, or reduce the severity of, hypokalemia. Patients at such high risk may be identified prior to their developing hypokalemia. Such a patient may be an adult patient with endogenous Cushing's Syndrome having type 2 diabetes mellitus or glucose intolerance to control hyperglycemia secondary to hypercortisolism. Patients may be identified by an above-threshold level of ACTH or cortisol in a patient sample taken post-GRM administration or pre-GRM administration, respectively. Upon identifying such a patient prior to the development of low potassium, the present methods provide for prophylactically treating the patient by administration of one or more hypokalemia treatments concurrently with an increased dose of GRM or with an initial dose of GRM to prevent hypokalemia.
-
公开(公告)号：US20180127478A1
公开(公告)日：2018-05-10
申请号：US15706538
申请日：2017-09-15
申请人： Wei-Chiang Shen , Li Zhou , Jennica Zaro
发明人： Wei-Chiang Shen , Li Zhou , Jennica Zaro
CPC分类号： C07K14/61 , A61K38/00 , A61P5/06 , C07K2319/30
摘要： Disclosed herein is a recombinant polypeptide comprising two single chain Fc domains fused or covalently attached to each other by a peptide linker, with the proviso that the peptide linker does not comprise an antibody hinge domain (also referred to herein as an “sc(Fc)2 construct”). In a further aspect, the recombinant polypeptide also comprises, or alternatively consists essentially of, or yet further consists of a first therapeutic moiety. Methods for use of the polypeptides, as well as methods for making same, are provided herein.
-
-
-
-
-
-
-
-
-
搜索结果
20 条记录 (耗时 0.022 秒)
